BioXcel Therapeutics (BTAI) Amortization - Deferred Charges (2022 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Amortization - Deferred Charges of $502000.0 in Q1 2026, up 7.04% quarter-over-quarter from $469000.0 in Q4 2025, and up 43.43% on a YoY basis from $350000.0 in Q1 2025.
BioXcel Therapeutics (BTAI) Amortization - Deferred Charges (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Amortization - Deferred Charges history runs 5 years deep, the most recent figure standing at $502000.0 for Q1 2026.
- In Q1 2026, Amortization - Deferred Charges rose 43.43% year-over-year to $502000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 133.2% YoY), while the FY2025 annual figure was $1.7 million, up 253.75% from the prior year.
- Amortization - Deferred Charges was $502000.0 for Q1 2026 at BioXcel Therapeutics, up from $469000.0 in the prior quarter.
- In the past five years, Amortization - Deferred Charges ranged from a high of $502000.0 in Q1 2026 to a low of $43000.0 in Q1 2024.
- Historically, Amortization - Deferred Charges has averaged $303437.5 across 5 years, with a median of $327500.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Amortization - Deferred Charges plunged 87.09% in 2024, then surged 713.95% in 2025.
- A 5-year view of Amortization - Deferred Charges shows it stood at $322000.0 in 2022, then fell by 4.66% to $307000.0 in 2023, then declined by 27.69% to $222000.0 in 2024, then soared by 111.26% to $469000.0 in 2025, then grew by 7.04% to $502000.0 in 2026.
- The last three Amortization - Deferred Charges figures came in at $502000.0 (Q1 2026), $469000.0 (Q4 2025), and $441000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | 502,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 502,000.00 |
| Mar 31, 2026 | 502,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Dec 31, 2025 | 469,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Jun 30, 2025 | 393,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Dec 31, 2023 | 307,000.00 |